samples (0.5 g × 12 months; total, 6 g per person) were prepared, and each pool was regarded as a representative sample of each set. In addition, 2 brands of commercially pooled human serum ("L-Consera N" and "L-Suitrol I," both purchased from Nissui Pharmaceutical, Tokyo, Japan) were used as in-house reference materials. The mean ± standard deviation (SD) age of the 10 participants was 22 ± 1 years (range, 18–22 years). The mean ± SD abstinence time was 3.1 ± 0.4 days (range, 2.6–3.8 days).

Chemicals: Standard mixture solutions of native PBDEs (BDE-AAP-A-15X) were purchased from AccuStandard (New Haven, CT, USA), and $^{13}C_{12}$-labeled PBDEs (MBDE-MXC) were purchased from Wellington Laboratories (Ontario, Canada). In this study, 29 PBDE congeners having 3 to 7 bromine atoms were monitored. The PBDE numbers are assigned according to the IUPAC PCB nomenclature. Acetone, acetonitrile, and n-hexane of pesticide analysis grade; ammonium sulfate of biochemistry grade; and 44% sulfuric acid-impregnated silica gel and n-nonane of dioxin analysis grade were purchased from Wako Pure Chemicals (Osaka, Japan). Water was deionized and purified using a Milli-Q cartridge system (Millipore, Bedford, MA, USA).

Sperm analysis: Sperm analyses were performed at the Department of Urology, St. Marianna University School of Medicine, according to the World Health Organization's recommendations as described elsewhere[5].

Serum PBDE measurements: Serum samples were analyzed at Osaka Prefectural Institute of Public Health. The serum sample (6 g) was extracted using ethanol/n-hexane (1:3 v/v, 14 mL) in a 50 mL test tube, after adding $^{13}C_{12}$-labeled surrogate standards ($^{13}C_{12}$-2,4,4′-tribromodiphenyl ether ($^{13}C_{12}$-TrBDE-28), $^{13}C_{12}$-2,2′,4,4′-tetrabromodiphenyl ether ($^{13}C_{12}$-TeBDE-47), $^{13}C_{12}$-2,2′,4,4′,5-pentabromodiphenyl ether ($^{13}C_{12}$-PeBDE-99), $^{13}C_{12}$-2,2′,4,4′,5,5′-hexabromodiphenyl ether ($^{13}C_{12}$-HxBDE-153), $^{13}C_{12}$-2,2′,4,4′,5,6′-HxBDE ($^{13}C_{12}$-HxBDE-154), and $^{13}C_{12}$-2,2′,3,4,4′,5′,6-heptabromodiphenyl ether ($^{13}C_{12}$-HpBDE-183); 10 pg for each congener) and 3.6 mL saturated ammonium sulfate solution. The test tube was shaken for 30 min and then centrifuged for 10 min at 3000 rpm. The n-hexane phase was collected, and the aqueous phase was re-extracted twice with 12 mL n-hexane. The 3 n-hexane phases were combined and washed with 12 mL water. After evaporation of the solvent, the lipid content was determined gravimetrically with a semimicro balance (Sartorius RC210P, Goettingen, Germany). The lipid was dissolved in n-hexane and was transferred to a column of 44% sulfuric acid-impregnated silica gel (3 g). The column was eluted with 30 mL n-hexane, and the eluate was evaporated to 2 mL. The n-hexane solution was transferred to a test tube and partitioned with n-hexane-saturated acetonitrile (4 mL) 3 times by shaking the test tube for 10 min and then centrifuging for 10 min at 3000 rpm. The acetonitrile phase was combined and then evaporated to dryness. The residue was redissolved in n-hexane and was transferred to a microconcentration tube. After addition of the injection standard ($^{13}C_{12}$-3,3′,4,4′,5-PeBDE) and keeper solvent (10 μL n-nonane), the extract was finally evaporated to approximately 10 μL under a gentle stream of nitrogen. The serum extract was assayed by a gas chromatography/mass spectrometry (GC/MS) system (Agilent 6890A GC coupled with JEOL JMS-GCmateII, Tokyo, Japan) with a fused silica capillary column (Rtx-1MS, 15 m, 0.25 mm i.d., 0.1 μm; Restek, Bellefonte, PA, USA). For each compound, 2 ions of the molecular ion or fragment ion cluster were monitored. Quantitation was based on the isotope dilution method using $^{13}C_{12}$-labeled internal standards. The PBDE concentrations were adjusted for total serum lipids and are expressed in units of nanogram per gram lipid weight (ng·g^{-1} lw). TeBDE-47, PeBDE-99, PeBDE-100, and HxBDE-153 were of interest because they are dominant in human serum.

Quality assurance and quality control: We validated the serum extraction procedure before beginning sample analysis by analyzing 4 replicate samples of pooled serum fortified with target analytes at 0.04–0.1 ng·g^{-1} serum. The mean percent recovery of 7 representative PBDE congeners (TrBDE-28, TeBDE-47, PeBDE-99, PeBDE-100, HxBDE-153, HxBDE-154, and HpBDE-183) ranged from 91% to 107%, and the relative standard deviation (RSD) ranged from 2% to 10%. The limit of detection (LOD) and limit of quantification (LOQ) were defined as 3 times and 10 times of the SD values obtained from the analysis of the 7 blank samples. However, for congeners that could not be detected in the blanks, values that were 3 times and 10 times of the SD values that were obtained from the analysis of 5 replicates of the lowest calibration standard were used as LOD and LOQ. The LOD values for all the PBDE congeners were below 0.3 ng·g^{-1} lw. In the analysis of 3 split unfortified serum samples, the RSD values for all the detected congeners were below 10%.

Results and Discussion

Of the 29 PBDE congeners monitored, 4 congeners (TeBDE-47, PeBDE-99, PeBDE-100, and HxBDE-153) were mainly detected in human serum samples (Figure 1). The concentrations of the detected PBDE congeners in the serum samples (n = 10) are shown in Table 1. The median levels of the individual PBDE congeners were as follows: BDE-47, 1.4 ng·g^{-1} lw; BDE-99, 0.21 ng·g^{-1} lw; BDE-100, 0.24 ng·g^{-1} lw; and BDE-153, 0.72 ng·g^{-1} lw. The levels of total PBDEs in Japanese human serum samples were almost the same as those reported in European countries but were one order of magnitude lower than those reported in USA[6]. Significant positive correlations were observed between the concentrations of TeBDE-47 and PeBDE-99 (r = 0.988, p < 0.001), TeBDE-47 and PeBDE-100 (r = 0.938, p < 0.001), and between PeBDE-99 and PeBDE-100 (r = 0.915, p < 0.001). In contrast, no significant correlations were observed between the concentration of HxBDE-153 and those of the other 3 congeners (r = 0.306–0.390, p = 0.26–0.39). The absence of a significant correlation between HxBDE-153 and the other dominant 3 congeners (TeBDE-47, PeBDE-99, and PeBDE-100) means that the main sources and/or biological properties of HxBDE-153

Fig.1 Chromatograms of PBDEs in human serum (participant No.2) and standard solution (1 to 2.5 ng·mL^{-1} each)

were different from those of the other 3 congeners. It has been reported that the technical mixtures of pentaBDE (DE-71 and Bromkal 70-5DE) and octaBDE (DE-79 and Bromkal 79-8DE) both contained HxBDE-153 in the range 5.32–5.44% w/w and 0.15–8.66% w/w, respectively[7]. The congeners TeBDE-47, PeBDE-99, and PeBDE-100 have been found in pentaBDE as the major components, but they have not been found in octaBDE[7]. These 3 congeners and HxBDE-153 have never been found in a technical decaBDE mixture (Saytex 102E and Bromkal 82-0DE)[7]. Therefore, TeBDE-47, PeBDE-99, and PeBDE-100 are mainly sourced from pentaBDE, although HxBDE-153 is sourced from both pentaBDE and octaBDE. In the early 1990s, Japanese manufacturers

Table 1 Concentrations of PBDEs in serum samples from 10 Japanese males (ng·g^{-1} lw)

| Congener | Participant No. | | | | | | | | | |
	1	2	3	4	5	6	7	8	9	10
TrBDE-17	tr <0.04	tr <0.05	nd <0.01	nd <0.01	nd <0.02	nd <0.01	nd <0.02	nd <0.01	nd <0.02	nd <0.02
TrBDE-28/33	tr <0.2	0.37	0.16	tr <0.2	0.16	0.24	tr <0.2	0.17	tr <0.2	tr <0.2
TrBDE-37	tr <0.02	tr <0.03	nd <0.01	nd <0.01	nd <0.01	nd <0.01	nd <0.01	nd <0.01	nd <0.01	nd <0.01
TeBDE-49	nd <0.02	nd <0.03	0.09	tr <0.07	tr <0.08	0.07	nd <0.02	0.09	nd <0.03	tr <0.09
TeBDE-47	1.3	5.9	1.5	0.96	1.6	1.8	0.54	2.9	0.93	0.81
TeBDE-66	nd <0.04	nd <0.05	nd <0.04	nd <0.04	nd <0.04	nd <0.04	nd <0.04	tr <0.2	nd <0.05	nd <0.05
PeBDE-100	0.23	0.67	0.24	0.21	0.24	0.40	0.13	0.31	0.21	0.25
PeBDE-99	0.21	1.1	0.21	0.16	0.25	0.21	0.10	0.49	0.15	0.20
PeBDE-118	0.02	0.03	tr <0.02	tr <0.02	0.02	0.03	tr <0.02	tr <0.02	0.03	0.03
PeBDE-85	tr <0.07	tr <0.09	tr <0.07	nd <0.02	tr <0.08	nd <0.02	nd <0.02	tr <0.07	nd <0.03	nd <0.02
HxBDE-155	nd <0.02	tr <0.07	tr <0.05	tr <0.05	nd <0.02	tr <0.06	nd <0.02	nd <0.02	tr <0.07	nd <0.02
HxBDE-154	tr <0.06	0.08	0.05	0.05	tr <0.06	0.06	tr <0.06	tr <0.06	tr <0.07	tr <0.07
HxBDE-153	0.76	0.96	1.1	0.56	0.58	0.68	0.37	0.52	0.91	0.79
HpBDE-183	nd <0.1	nd <0.2	tr <0.4	tr <0.4	tr <0.4	tr <0.4	nd <0.1	nd <0.1	tr <0.5	nd <0.2
Sum of 4 PBDEs*	2.5	8.6	3.1	1.9	2.7	3.1	1.1	4.2	2.2	2.1

Abbreviations: tr, trace; nd, not detected. *Sum of TeBDE-47, PeBDE-100, PeBDE-99, and HxBDE-153.

voluntarily stopped the production and use of pentaBDE because of concern for its potency to accumulate in biota and to produce toxic polybrominated dibenzofurans/dioxins under thermal stresses. However, the production and use of octaBDE were continued in Japan until the early 2000s. There may still be a large number of consumer products that contain octaBDE in the Japanese indoor environment. Thus, with regard to octaBDE components such as HxBDE-153 and HpBDE-183, inhalation and dermal exposure may be important exposure routes for the Japanese people.

The sperm concentration and testis size of the 10 participants are shown in Table 2. The sperm concentration of these participants ranged from 25 to 115 million·mL^{-1}. No participant had a sperm concentration below 20 million·mL^{-1}, a preliminary diagnostic value of male infertility. Clear inverse correlations were observed between serum HxBDE-153 concentration and sperm concentration ($r = -0.841$, $p = 0.002$, Fig.2) and testis size ($r = -0.764$, $p = 0.01$). However, no significant relationships were observed

Table 2   Sperm concentration and testis size of 10 Japanese males

	Participant No.									
	1	2	3	4	5	6	7	8	9	10
Sperm concentration (million·mL^{-1})*	49	55	38	108	83	74	115	78	25	30
Testis size (mL)	36	36	40	50	46	42	51	54	29	33

*Annual average of monthly data.

Fig.2   Relationship between serum HxBDE-153 concentration and sperm concentration

between the serum concentrations of any of the other congeners and the sperm concentration or testis size. Researchers have hypothesized that endocrine disrupting chemicals with thyroid hormonal or sexual hormonal activities may adversely affect male fertility. The thyroid-disrupting and estrogenic/antiestrogenic activities of PBDEs have been reported in several studies[1, 3]. In addition, considerable evidence is available for the reproductive effects of PBDEs from in vivo studies. Kuriyama et al. have reported that developmental exposure to a single low dose (60 µg·kg^{-1} body weight) of PeBDE-99 decreased sperm counts in male Wistar rats[4]. Although the levels of PBDEs found in our study are relatively low, we observed significant inverse associations between the serum concentration of HxBDE-153 and sperm concentration and testis size; this suggests an association between serum HxBDE-153 concentration and human sperm quality. The lack of a significant relationship among other individual PBDE congeners and sperm parameters may indicate a difference in bioactivity between congeners. The relationship between PBDEs and sperm quality is a complicated problem and needs further study.

Acknowledgments

References
1. Zhou T, Taylor MM, DeVito MJ, Crofton KM. *Toxicol Sci* 2002; 66:105.
2. Eriksson P, Jakobsson E, Fredriksson A. *Environ Health Perspect* 2001; 109:903.
3. Meerts IA, Letcher RJ, Hoving S, Marsh G, Bergman A, Lemmen JG, van der Burg B, Brouwer A. *Environ Health Perspect* 2001; 109:399.
4. Kuriyama SN, Talsness CE, Grote K, Chahoud I. *Environ Health Perspect* 2005; 113:149.
5. Iwamoto T, Nozawa S, Yoshiike M, Hoshino T, Baba K, Matsushita T, Tanaka SN, Naka M, Skakkebaek NE, Jorgensen N. *Hum Reprod* 2006; 21:760.
6. Hites RA. *Environ Sci Technol* 2004; 38:945.
7. La Guardia MJ, Hale RC, Harvey E. *Environ Sci Technol* 2006; 40:6247.

Taylor & Francis
Taylor & Francis Group

Occurrence of polybrominated diphenyl ethers and polychlorinated biphenyls in shark liver oil supplements

KAZUHIKO AKUTSU[1,2], YUKIO TANAKA[2], & KAZUICHI HAYAKAWA[2]

[1]*Division of Food Chemistry, Osaka Prefectural Institute of Public Health, 1-3-69, Nakamichi, Higashinari-ku, Osaka 537-0025, Japan and* [2]*Graduate School of Natural Science and Technology, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan*

Abstract
Results are reported of a pilot survey of concentrations of polybrominated diphenyl ethers (PBDEs) and polychlorinated biphenyls (PCBs) in shark liver oil supplements. Eleven brands of dietary supplements were analysed using an isotope dilution GC/MS method. Total concentrations of 10 PBDE congeners (BDE-28, −47, −49, −66, −99, −100, −153, −154, −155 and −183) ranged from 0.1 to 53 ng g^{-1} oil weight and total concentrations of six PCB congeners (CB-28/31, −52, −118, −153 and −180) in the samples ranged from 16 to 340 ng g^{-1} oil weight (undetected values are not included). Two brands of Japanese deep-sea shark liver oil contained the highest levels of PBDEs (49–53 ng g^{-1} oil weight) and PCBs (290–340 ng g^{-1} oil weight). These results indicate that PBDEs may have entered Japanese deep-sea waters.

Keywords: *Dietary supplements, shark liver oil, polybrominated diphenyl ethers, polychlorinated biphenyls*

Introduction

In recent years, deep-sea shark liver oil has become popular as a dietary supplement. This oil contains some therapeutic ingredients, such as squalene, alkylglycerols, squalamine and $n-3$ polyunsaturated fatty acids. Squalene and alkylglycerols have been shown to enhance immune functions in animal models (Pugliese et al. 1998; Kelly 1999), and squalamine has been shown to have some antimicrobial and antitumor activities (Moore et al. 1993; Sills et al. 1998). In addition, it is generally accepted that the consumption of $n-3$ polyunsaturated fatty acids reduces the risk of cardiovascular and certain allergic diseases (Arab 2003; Calder 2003). Owing to these potential bioactivities, deep-sea shark liver oil has been claimed to be effective against cancers and infectious/inflammatory diseases, and its use has been promoted for different age groups, including children.

However, it should be noted that raw shark liver oil may contain considerable amounts of persistent organic pollutants, such as polychlorinated biphenyls (PCBs). Berg et al. (1998) have reported the concentrations of total PCBs (a sum of 31 congeners) in 10 liver samples of velvet belly sharks collected from a depth of about 400 m in Nordfjord, Norway (Berg et al. 1998). Mean concentration of total PCBs was 2390 ng g^{-1} lipid weight with a range of 1470–3870 ng g^{-1} lipid weight. Takahashi et al. (1998) have determined the concentrations of PCBs in the pooled liver samples of dogfish sharks collected from the bathyal zone (220–540 m depth) of Suruga Bay, Japan. This concentration was 1000 ng g^{-1} lipid weight.

De Boer et al. (1998) found relatively high concentrations of polybrominated diphenyl ethers (PBDEs) in sperm whales, indicating the contamination of deep-sea ecosystems by PBDEs. PBDEs are used as flame retardants in the production of common consumer products, such as electronics, furniture and textiles. As PBDEs are not chemically

bound to the materials, they can leak into the environment during the production, use and disposal of the product. They are persistent and bioaccumulative, and have been shown to alter thyroid homeostasis in animal studies (Zhou et al. 2002). PBDEs have been recognized as environmental pollutants of global concern because their levels in the environment and in humans have increased markedly over the past several decades (Meironyté et al. 1999; Ikonomou et al. 2002; Akutsu et al. 2003; Sjödin et al. 2004). PBDEs have been detected in edible fish and other foodstuffs (Akutsu et al. 2001; Ohta et al. 2002; Bocio et al. 2003; Domingo 2004). It has been reported that fish and shellfish are the major contributors to human intake of PBDEs in European countries and Japan (Joint FAO/WHO Expert Committee on Food Additives (JECFA) 2005). Processed fishery products may also be significant contributors to the total intake of PBDEs in humans. A recent study by Jacobs et al. (2004) reported that 16 of 17 dietary fish oil supplements contain PBDEs, in addition to traditional organochlorine pollutants, such as PCBs. However, the levels of PBDEs in shark liver oil supplements remain unclear. To the best of our knowledge, there has only been one analytical result reported for PBDEs in a UK brand shark liver oil (UK Food Standards Agency 2006).

The aim of this study was to determine PBDE and PCB concentrations in dietary shark liver oil supplements. Determination of these concentrations enabled a comparison of the two classes of contaminants.

Materials and methods

Chemicals

Ten PBDE congeners (BDE-28, −47, −49, −66, −99, −100, −153, −154, −155 and −183) and six PCB congeners (CB-28/31, −52, −118, −153 and −180) were measured in this study. Single congener solutions of each native PBDE (BDE-28, −47, −49, −66, −99, −100, −153, −154, −155 and −183) and $^{13}C_{12}$-labeled PBDE ($^{13}C_{12}$-BDE-28, −47, −77, −99, −153, −154 and −183) were purchased from Cambridge Isotope Laboratories (Cambridge, MA, USA) and Wellington Laboratories (Ontario, Canada). Standard mixture solutions of native PCBs (CB-28, −52, −118, −153 and −180) and $^{13}C_{12}$-labeled PCBs ($^{13}C_{12}$-CB-28, −52, −118, −153 and −180) were purchased from Cambridge Isotope Laboratories. The CB and BDE numbers are assigned according to the IUPAC PCB nomenclature (US Environmental Protection Agency Webpage). Acetone, cyclohexane, hexane and

anhydrous sodium sulfate of pesticide analysis grade, dimethyl sulfoxide (DMSO) of biochemistry grade and 44% sulfuric acid-impregnated silica gel of dioxin analysis grade were purchased from Wako (Osaka, Japan). Water was deionized and purified using a Milli-Q cartridge system (Millipore, Bedford, MA, USA) and was then washed with hexane.

Sample collection and preparation

A total of 11 brands of dietary shark liver oil supplement were purchased from two Japanese retailers between January and June, 2004 (Table I). All the oil supplements were in capsule form. The capsule shells were removed and the oils combined to form a single batch sample for each product. For comparison, two different batches (manufactured on two different dates) of the same brand of Japanese shark liver oil (SLO1A and SLO1B) were separately analysed. Since the samples considered included only the leading brands available in the Japanese market, this was not a comprehensive survey of all the available brands.

Cleanup procedure

A previously developed method for analysing PBDEs in fish (Akutsu et al. 2001) was modified and employed in this study. In brief, a sample (0.75 g) was spiked with a surrogate standard solution containing $^{13}C_{12}$-PBDEs ($^{13}C_{12}$-BDE-28, −47, −99, −153, −154 and −183; 0.75 ng each) and $^{13}C_{12}$-PCBs ($^{13}C_{12}$-CB-28, −52, −118, −153, and −180; 0.75 ng each) and was then purified by gel permeation chromatography (GPC) using the AS-2000 system (ABC Laboratories, Columbia, MO, USA) equipped with a Shodex (Tokyo, Japan) GPC column EV-G (guard column, 100×20 mm I.D.) and EV-2000 (300 × 20 mm I.D.). The column was eluted with acetone/cyclohexane (3:7, v/v) at 40°C. The first 70 ml of the eluate was discarded to remove the bulk of lipids and the next 70 ml was collected. This fraction was evaporated to dryness and additional cleanup was done using a 44% sulfuric acid-impregnated silica gel column (3 g) using 30 ml of hexane as the eluent. The hexane solution was concentrated to a volume of 4 ml and then extracted three times with 10 ml of DMSO. Water (30 ml) was added to the combined DMSO phase and back extraction was performed three times with 30 ml of hexane. The combined hexane phase was concentrated to 50 µl of nonane with an injection standard ($^{13}C_{12}$-BDE-77, 0.5 ng).

GC/MS condition

The analysis was performed using an Agilent gas chromatograph (model 6890A) equipped with a

Table I. Sample information.

Sample code	Oil composition	Country of origin	Indicated concentrations of SQ, AG and $n-3$ PUFAs	Proposed dose $(g\,day^{-1})^1$
SLO1A*	SLO (cold processed)	Japan	SQ 82%–89%, AG 6%–11%, $n-3$ PUFAs 3%–7%	0.75–1.75
SLO1B*	SLO (cold processed)	Japan	SQ 82%–89%, AG 6%–11%, $n-3$ PUFAs 3%–7%	0.75–1.75
SLO2	SLO (cold processed)	Japan	SQ 82%–89%, AG 6%–11%, $n-3$ PUFAs 3%–7%	0.75–1.75
SLO3	SLO (cold processed)	New Zealand	SQ 44.4%, AG 35.4%, $n-3$ PUFAs 6.7%	1.8
SLO4	SLO (cold processed)	New Zealand	SQ 30%–55%, AG 20%–45%	1.5
SLO5	SLO (cold processed), VE	New Zealand	NA	0.6–1.2
SLO6	SLO	NA	SQ > 99.9%	2.6
SLO7	SLO	NA	SQ > 99%	1.8–2.7
SLO8	SLO	NA	SQ 100%	0.5
SLO9	SLO	NA	NA	0.9–1.2
SLO10	SLO, VE	NA	NA	0.6–1.5
SLO11	SLO (92.5%) + FO (7.1%), VE, VA	NA	SQ 92%	2.2–2.8

SLO, deep-sea shark liver oil; FO, fish oil; VE, vitamin E; VA, vitamin A; PUFAs, polyunsaturated fatty acids; SQ, squalene; AG, alkylglycerol; NA, not available.
*SLO1A and SLO 1B are of the same brand but from different batches.
[1]Proposed doses are based on the information provided by the product manufacturers/suppliers.

JMS-GC mate II mass spectrometer (JEOL, Tokyo, Japan). The separation was carried out in an Rtx-1MS fused-silica capillary column (15 m × 0.25 mm I.D., 0.1 μm film thickness with a 3-m Integra-Guard column; Restek, Bellefonte, PA, USA) using helium as the carrier gas (flow rate 1 ml min^{-1}). The injector temperature was 250°C and the injection volume was 2 μl (splitless). The column temperature was programmed from 100°C (2 min) to 310°C (3 min) at a rate of 10°C min^{-1}. The mass spectrometer was operated in electron ionization mode with selected ion monitoring (35 eV, resolution 1000). The ion source and interface temperatures were 280 and 310°C, respectively. The PBDE and PCB congeners were monitored at the two most intensive ions of the molecular ion cluster and were quantified by the isotope dilution method using the corresponding $^{13}C_{12}$-labelled congeners.

Quality assurance and quality control

Spiked sample recoveries of PBDEs and PCBs were in the range of 80–110% with relative standard deviation of less than 5% (spiking level: each 1 ng g^{-1} oil weight). The overall recoveries of the $^{13}C_{12}$-labelled congeners ranged from 65 to 97%. The detection limits of the individual PBDE and PCB congeners varied from 0.05 to 0.5 ng g^{-1} oil weight.

Results and discussion

Concentrations of the PBDEs and PCBs are summarized in Tables II and III. In 11 of the 12 analysed samples, BDE-47 was observed to be the most abundant PBDE congener; BDE-183 was not

detected in any samples. In 10 of the 12 analysed samples, CB-153 was the most abundant congener. The predominance of both BDE-47 and CB-153, and the absence of BDE-183, are in accordance with previously reported findings on cod liver oil (Jacobs et al. 2004). The total concentrations of the 10 PBDEs (sum of BDE-28, −47, −49, −66, −99, −100, −153, −154, −155 and 183) in the 11 samples ranged from 0.1 to 53 ng g^{-1} oil weight, and the total concentrations of the six indicator PCBs (sum of CB-28/31, −52, −118, −153 and −180) ranged from 16 to 340 ng g^{-1} oil weight (undetected values are not included). Total concentrations of the 10 PBDEs were lower than those of the six PCBs in all samples. The lowest value of BDE-47 in our study (0.1 ng g^{-1} oil weight) is similar to the value measured in the UK brand shark liver oil supplement (0.17 ng g^{-1} whole weight) (UK Food Standards Agency 2006). The three samples from the two brands of Japanese deep-sea shark liver oil (SLO1A, SLO1B and SLO2) exhibited the highest values for the sum of the 10 PBDEs (49–53 ng g^{-1} oil weight) and the six PCBs (290–340 ng g^{-1} oil weight). These levels were close to those found in pure cod liver oil in the UK market (sum of seven PBDEs, 20–34 ng g^{-1} lipid weight; sum of seven PCBs, 97–202 ng g^{-1} lipid weight) (Jacobs et al. 2004).

The two brands of Japanese shark liver oil (SLO1A, SLO1B and SLO2) were manufactured using the same special method (Japanese patent application no. 2002-84971). This method comprises the following four steps: (i) cold centrifugal extraction, (ii) mesh filtration, (iii) deoxygenation by vacuum, and (iv) deodorization using nitrogen flow. In this method, there was no heating step and only

Table II. Concentrations of PBDEs in deep-sea shark liver oil.

| Sample code | PBDE (ng g⁻¹ oil weight) | | | | | | | | | | | |
	28	49	47	66	100	99	155	154	153	183	Sum[1] (lower bound)	Sum[2] (upper bound)
SLO1A*	0.9	2.3	23	2.6	5.2	8.0	1.5	2.5	2.9	ND	49	49
SLO1B*	1.0	2.5	28	2.8	3.6	8.2	1.3	2.7	2.4	ND	53	53
SLO2	1.1	2.6	28	2.3	4.3	7.5	1.2	2.4	2.1	ND	52	52
SLO3	ND	0.1	0.6	ND	ND	ND	ND	ND	ND	ND	0.7	1.9
SLO4	ND	0.1	0.5	ND	ND	ND	ND	ND	ND	ND	0.6	1.8
SLO5	ND	0.1	0.1	ND	ND	ND	ND	ND	ND	ND	0.2	1.4
SLO6	ND	ND	0.1	ND	ND	ND	ND	ND	ND	ND	0.1	1.4
SLO7	ND	ND	0.3	0.2	ND	ND	ND	ND	ND	ND	0.5	1.7
SLO8	ND	ND	1.3	0.1	1.8	5.6	2	2.5	1.6	ND	15	16
SLO9	ND	ND	0.1	ND	ND	ND	ND	ND	ND	ND	0.1	1.4
SLO10	ND	ND	0.3	ND	ND	ND	ND	ND	ND	ND	0.3	1.6
SLO11	ND	ND	0.1	ND	ND	ND	ND	ND	ND	ND	0.1	1.4

ND, not detected (<0.5 ng g⁻¹ oil weight for BDE-183 and <0.1 ng g⁻¹ oil weight for the other nine PBDE congeners).
*SLO1A and SLO1B are of the same brand but from different batches.
[1]The concentrations of "ND" congeners were assumed to be zero.
[2]The concentrations of "ND" congeners were assumed to be the detection limit.

Table III. Concentrations of PCBs in deep-sea shark liver oil.

| Sample code | PCB (ng g⁻¹ oil weight) | | | | | |
	28/31	52	118	153	180	Sum
SLO1A*	5.6	18	68	170	82	340
SLO1B*	5.5	20	63	150	81	320
SLO2	4.1	17	57	140	69	290
SLO3	0.2	0.8	7.6	20	14	43
SLO4	0.2	0.6	5.2	4.9	11	22
SLO5	0.3	1.0	3.6	9.1	4.9	19
SLO6	0.5	3.4	8.9	9.3	6.7	29
SLO7	0.2	0.7	1.6	16	12	31
SLO8	0.1	0.1	0.2	1.1	16	18
SLO9	0.2	0.3	0.9	9.0	7.4	18
SLO10	0.3	0.5	2.1	10	6.1	19
SLO11	0.3	0.2	0.7	8.6	6.2	16

*SLO1A and SLO1B are of the same brand but from different batches.

gentle, non-chemical refining steps were adopted to prevent the destruction of unstable ingredients in the shark liver oil. The present study demonstrated that such "cold processed" (virtually unrefined) products may contain considerable amounts of PBDEs and PCBs. Similar cold processed products derived from the deep-sea sharks in New Zealand (SLO3, SLO4 and SLO5) were also contaminated with PBDEs and PCBs. However, the levels of these compounds were one or two orders of magnitude lower than those found in the Japanese shark products (Tables II and III). This result suggests that the Japanese sharks are more contaminated than those from New Zealand. Several studies have shown that the concentrations of PCBs and other organochlorine pollutants are higher in marine mammals from the Northern Hemisphere than those from the Southern Hemisphere (Tanabe et al. 1994; Schröder and Castle 1998). More recently, Ueno et al. (2003, 2004) have reported the geographical distribution of PCB and PBDE concentrations in skipjack tuna collected from the offshore waters of Asia and have speculated that Japan and other countries around the East China Sea are "hot spots" that release PCBs and PBDEs into the marine environment. In contrast, Scobie et al. (1999) reported that the estuarine environment in New Zealand is relatively free of organochlorine contaminants; for example, PCB concentrations in the estuarine sediments of New Zealand (0.12–8.8 μg kg⁻¹ dry weight) were lower than those reported in Japan (63–240 μg kg⁻¹ dry weight) and Sweden (23–262 μg kg⁻¹ dry weight). Thus, it is likely that deep-sea sharks in the Northern Hemisphere tend to possess higher levels of these pollutants than those in the Southern Hemisphere; however, further studies are required to confirm this fact. According to the product specifications, the two brands of Japanese shark liver oil were obtained from selected bathyal sharks (*Centrophoridae* and *Squalidae*) captured using long-line fishing in waters approximately 600–800 m deep around the Goto Islands (50 km off the west coast of Kyushu, Japan). Our results suggest that PBDEs may have entered Japanese deep-sea waters. In the marine environment, the deep sea and its ecosystems will be the ultimate sinks for PBDEs.

PBDE and PCB congener profiles of the three samples from Japanese shark liver oil (SLO1A, SLO1B and SLO2) were almost identical. For PBDEs, the contributions of the nine PBDEs to the total concentration were as follows: BDE-47: 47–54%; BDE-99: 15–16%; BDE-100: 8–11%;

Figure 1. Chromatograms of PBDEs in deep-sea shark liver oil using GC/MS based on the isotope dilution method.

BDE-66: 4.5–5.3%; BDE-154: 4.7–5.1%; BDE-49: 4.7–5.0%; BDE-153: 4.1–5.9%; BDE-155: 2.3–3.1%; BDE-28: 1.8–2.1%. For PCBs, the contributions of the six PCBs to the total concentration were as follows: CB-28/31: 1.4–1.7%; CB-52: 5.2–6.3%; CB-118: 20%; CB-153: 47–49%; CB-180: 24–25%. Example chromatograms of tetra- to hexa-BDEs in Japanese shark liver oil (SLO1A) are shown in Figure 1. Although the known contributions of BDE-28, −49, −66 and −155 in chemical PBDE mixtures (e.g. Bromkal 70-5DE and 79-8DE) are almost negligible (Ikonomou et al. 2002), we observed these minor congeners in clear proportions together with five major congeners (BDE-47, −99, −100, −153 and −154) in the Japanese shark liver oil samples (Table II and Figure 1). Similar proportions have also been reported in salmon (Hites et al. 2004). BDE-28, −49, −66 and −155 are likely to be efficiently biomagnified in these predatory species through the aquatic food chain.

The estimated daily intakes of PBDEs (10 congeners) and PCBs (six congeners) from the shark liver oil supplements according to the daily doses proposed by the product manufacturers/suppliers (Table I) are shown in Table IV. Intake of PBDEs was calculated using the upper bound concentrations for each of the products. Intake of the 10 PBDEs ranged from less than 0.001 to 0.09 µg day⁻¹. The maximum intake of the 10 PBDEs estimated in this study (0.09 µg day⁻¹) was comparable to or higher than the total dietary intake of PBDEs reported in Spain (0.097 µg day⁻¹), Sweden (0.051 µg day⁻¹) and Finland (0.044 µg day⁻¹) (Domingo 2004). The maximum intake of the 10 PBDEs (0.09 µg day⁻¹) was 0.075%

Table IV. Estimated daily intake ($\mu g\,day^{-1}$) of PBDEs and PCBs from deep-sea shark liver oil.

Sample code	Sum of ten PBDEs[1]	Sum of six PCBs
SLO1A*	0.04–0.09	0.26–0.60
SLO1B*	0.04–0.09	0.24–0.56
SLO2	0.04–0.09	0.22–0.51
SLO3	0.003	0.08
SLO4	0.003	0.03
SLO5	<0.001–0.002	0.01–0.02
SLO6	0.004	0.08
SLO7	0.003–0.005	0.06–0.08
SLO8	0.008	0.01
SLO9	0.001–0.002	0.02
SLO10	0.001–0.002	0.01–0.03
SLO11	0.003–0.004	0.04

*SLO1A and SLO1B are of the same brand but from different batches.
[1]Intakes of PBDEs were calculated using the upper bound concentrations for each product.

of the US EPA reference dose for penta-BDE (120 µg day⁻¹ for a 60-kg person) (Wenning et al. 2003). The intake of the six indicator PCBs ranged from 0.01 to 0.60 µg day⁻¹. Based on the data of the six indicator PCBs comprising 23–27% of the total PCBs (sum of all tri- to hepta-congeners) in the typical Japanese diet samples (Akutsu et al. 2005), it can be calculated that the maximum intake of total PCBs from shark liver oil supplements was 2 µg day⁻¹ (four times the intake of the six indicator PCBs). This level is less than 1% of the provisional tolerable daily intake of PCBs set by the Japanese government (300 µg day⁻¹ for a 60-kg person). Our data indicate that the frequent consumption of shark liver oil supplements will increase human dietary

exposure to PBDEs and PCBs, although the safety margins between the proposed toxic levels and the estimated intake of these pollutants are considerable. In addition, data regarding the safety of long-term use of shark liver oil supplements do not exist. Further research is needed to evaluate the potential risks and benefits of shark liver oil supplements.

Acknowledgments

References

Akutsu K, Obana H, Okihashi M, Kitagawa M, Nakazawa H, Matsuki Y, Makino T, Oda H, Hori S. 2001. GC/MS analysis of polybrominated diphenyl ethers in fish collected from the Inland Sea of Seto, Japan. Chemosphere 44:1325–1333.

Akutsu K, Kitagawa M, Nakazawa H, Makino T, Iwazaki K, Oda H, Hori S. 2003. Time-trend (1973–2000) of polybrominated diphenyl ethers in Japanese mother's milk. Chemosphere 53:645–654.

Akutsu K, Kuwabara K, Konishi Y, Matsumoto H, Murakami Y, Tanaka Y, Matsuda R, Hori S. 2005. Congener-specific analysis of PCBs in food samples by using GC/MS. Journal of the Food Hygienic Society of Japan 46:99–108, [English abstract available].

Arab L. 2003. Biomarkers of fat and fatty acid intake. Journal of Nutrition 133:925S–932S.

Berg V, Polder A, Skaare JU. 1998. Organochlorines in deep-sea fish from the Nordfjord. Chemosphere 38:275–282.

Bocio A, Llobet JM, Domingo JL, Corbella J, Teixido A, Casas C. 2003. Polybrominated diphenyl ethers (PBDEs) in foodstuffs: Human exposure through the diet. Journal of Agricultural and Food Chemistry 51:3191–3195.

Calder PC. 2003. Long-chain n-3 fatty acids and inflammation: Potential application in surgical and trauma patients. Brazilian Journal of Medical and Biological Research 36:433–446.

De Boer J, Wester PG, Klamer HJ, Lewis WE, Boon JP. 1998. Do flame retardants threaten ocean life? Nature 394:28–29.

Domingo JL. 2004. Human exposure to polybrominated diphenyl ethers through the diet. Journal of Chromatography A 1054:321–326.

Hites RA, Foran JA, Schwager SJ, Knuth BA, Hamilton MC, Carpenter DO. 2004. Global assessment of polybrominated diphenyl ethers in farmed and wild salmon. Environmental Science and Technology 38:4945–4949.

Ikonomou MG, Rayne S, Addison RF. 2002. Exponential increases of the brominated flame retardants, polybrominated diphenyl ethers, in the Canadian Arctic from 1981 to 2000. Environmental Science and Technology 36:1886–1892.

Jacobs MN, Covaci A, Gheorghe A, Schepens P. 2004. Time trend investigation of PCBs, PBDEs, and organochlorine pesticides in selected n-3 polyunsaturated fatty acid rich dietary fish oil and vegetable oil supplements; nutritional relevance for human essential n-3 fatty acid requirements. Journal of Agricultural and Food Chemistry 52:1780–1788.

Joint FAO/WHO Expert Committee on Food Additives (JECFA) (2005). Summary and conclusions of the sixty-fourth meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA); 2005 Feb. 8–17; Rome. p 31. Available: http://www.who.int/ipcs/food/jecfa/summaries/en/summary_report_64_final.pdf via the INTERNET. Accessed 11 January 2006.

Kelly GS. 1999. Squalene and its potential clinical uses. Alternative Medicine Review 4:29–36.

Meironyté D, Norén K, Bergman Å. 1999. Analysis of polybrominated diphenyl ethers in Swedish human milk. A time-related trend study, 1972–1997. Journal of Toxicology and Environmental Health A 58:329–341.

Moore KS, Wehrli S, Roder H, Rogers M, Forrest Jr JN, McCrimmon D, Zasloff M. 1993. Squalamine: An aminosterol antibiotic from the shark. Proceedings of the National Academy of Sciences of the United States of America 90:1354–1358.

Ohta S, Ishizuka D, Nishimura H, Nakao T, Aozasa O, Shimidzu Y, Ochiai F, Kida T, Nishi M, Miyata H. 2002. Comparison of polybrominated diphenyl ethers in fish, vegetables, and meats and levels in human milk of nursing women in Japan. Chemosphere 46:689–696.

Pugliese PT, Jordan K, Cederberg H, Brohult J. 1998. Some biological actions of alkylglycerols from shark liver oil. The Journal of Alternative and Complementary Medicine 4:87–99.

Schröder C, Castle P. (1998). Life history parameters and polychlorinated biphenyls (PCBs) in long-finned pilot whales (*Globicephala melas*) from New Zealand strandings: A report to WWF-New Zealand, June 1998. New Zealand: Victoria University of Wellington. Available: http://www.wwf.org.nz/conservation/stuff/PCB_report.pdf via the INTERNET. Accessed 23 February 2006.

Scobie S, Buckland S, Ellis H, Salter R. (1999). Organochlorines in New Zealand: Ambient concentrations of selected organochlorines in estuaries. Ministry for the Environment, Wellington, New Zealand. Available: http://www.mfe.govt.nz/publications/hazardous/organochlorine-concentration-in-estuaries-jun99.pdf via the INTERNET. Accessed 18 February 2006.

Sills Jr AK, Williams JI, Tyler BM, Epstein DS, Sipos EP, Davis JD, McLane MP, Pitchford S, Cheshire K, Gannon FH, et al. 1998. Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Research 58:2784–2792.

Sjödin A, Jones RS, Focant JF, Lapeza C, Wang RY, McGahee III EE, Zhang Y, Turner WE, Slazyk B, Needham LL, et al. 2004. Retrospective time-trend study of polybrominated diphenyl ether and polybrominated and polychlorinated biphenyl levels in human serum from the United States. Environmental Health Perspectives 112:654–658.

Takahashi S, Lee JS, Tanabe S, Kubodera T. 1998. Contamination and specific accumulation of organochlorine and butyltin compounds in deep-sea organisms collected from Suruga Bay, Japan. Science of the Total Environment 214:49–64.

Tanabe S, Iwata H, Tatsukawa R. 1994. Global contamination by persistent organochlorines and their ecotoxicological impact on marine mammals. Science of the Total Environment 154:163–177.

Ueno D, Takahashi S, Tanaka H, Subramanian AN, Fillmann G, Nakata H, Lam PK, Zheng J, Muchtar M, Prudente M, et al. 2003. Global pollution monitoring of PCBs

and organochlorine pesticides using skipjack tuna as a bioindicator. Archives of Environmental Contamination and Toxicology 45:378–389.

Ueno D, Kajiwara N, Tanaka H, Subramanian A, Fillmann G, Lam PK, Zheng GJ, Muchitar M, Razak H, Prudente M, et al. 2004. Global pollution monitoring of polybrominated diphenyl ethers using skipjack tuna as a bioindicator. Environmental Science and Technology 38:2312–2316.

US Environmental Protection Agency [internet]. PCB ID – Table of PCB congeners and other species. Available: http://www.epa.gov/toxteam/pcbid/table.htm. Accessed 7 July 2005.

UK Food Standards Agency [internet]. Brominated chemicals in farmed & wild fish & shellfish and fish oil dietary supplements. Available: http://www.food.gov.uk/multimedia/pdfs/fsis0406.pdf. Accessed 21 June 2006.

Wenning RJ, Von Burg A, Braithwaite S, Serex T, Campbell R, Shipp A, Lawrence G. 2003. Health risk assessment of the commercial pentabromodiphenyl ether product in the United States. Organohalogen Compounds 61:275–278.

Zhou T, Taylor MM, DeVito MJ, Crofton KM. 2002. Developmental exposure to brominated diphenyl ethers results in thyroid hormone disruption. Toxicological Sciences 66:105–116.

報　文

液体クロマトグラフィー/質量分析法による魚介類中の
ノニルフェノール及びオクチルフェノールの定量

堀江　正一[®1]，小林　晴美[1]，石井　里枝[1]，斉藤　貢一[2]，

中澤　裕之[2]，牧野　恒久[3]

　高速液体クロマトグラフィー/質量分析法（LC/MS）を用いた魚介類及び食肉中のノニルフェノール（4-NP）及びオクチルフェノール（4-OP）の簡易かつ迅速な定量法を検討した．前処理は，メタノールで抽出し，マルチモードカートリッジを用いて試験溶液を調製した．LC/MS 条件は，4-NP，4-OP 共ネガティブモードを用い，測定は脱プロトン化分子（m/z 205.1，219.1）を用いた選択イオン検出（selected ion monitoring, SIM）法を採用した．移動相は揮発性の酢酸（0.005%）及び酢酸アンモニウム（1 mM）を用いることにより，感度良く検出できた．SIM 法による検量線はいずれも 0.5～50 ng/mL の範囲で良好な直線性を示した．本法による 10 ng/g 添加時の回収率は 72.1～89.6%，標準偏差は 10% 以内であった．本法による検出限界は 0.5～2 ng/g であった．本法を用いて市販魚介類及び食肉について NP 及び OP の汚染実態調査を実施したところ，シジミ，ツブ貝等から微量の 4-NP が検出された．

1　緒　　言

　ノニルフェノール（NP），オクチルフェノール（OP）にはエストロゲン様作用があるとされ，内分泌系に対する撹乱作用が疑われている[1)2)]．NP，OP は非イオン性界面活性剤｛nonylphenolethoxylate（NPEO），octylphenolethoxylate（OPEO）｝や樹脂の安定剤や抗酸化剤の原材料として汎用されている．2000 年における NP，OP の生産量は約 16500 トン及び 10000 トンである．環境中へ放出された NPEO，OPEO は，生態系において容易に分解され，NP，OP を生成する[3)4)]．このことから，NP，OP の河川や下水処理水への汚染が問題視され，水生生物への影響が懸念されている．NP，OP の魚類に対するエストロゲン様作用は強いとされてきたが[5)6)]，NP については平成 13 年 8 月に，OP についても平成 14 年 6 月，魚類に対して内分泌撹乱作用が確認された[7)8)]．

　我々は，NP，OP に汚染された魚介類や容器包装から移行した食品を経由して，NP，OP を日常的に摂取している可能性がある．したがって，実際にヒトがどの程度 NP，OP に暴露されているか知ることは極めて重要である．現在まで，河川水，工場排水，土壌等の環境試料中の NP，OP 濃度については，液体クロマトグラフィー（LC），高速液体クロマトグラフィー/質量分析法（LC/MS），ガスクロマトグラフィー/質量分析法（GC/MS）法等を中心に数多くの報告がなされている．しかし，市販されている魚介類，食肉や食事中の分析例は少ない[9)～11)]．そこで今回，LC/MS を用いた魚介類，食肉中の NP，OP の高感度分析法を検討したので報告する．なお，NP，OP には分岐タイプと直鎖タイプの構造異性体があるが，工業用として使用され，環境中から検出されているものは専ら分岐タイプなので[12)13)]，分岐タイプの 4-NP 及び 4-t-OP を中心に検討した．

2　実　　験

2・1　試料及び試薬

　魚介類及び食肉は埼玉県内で市販されているものを用いた．

　標準品：4-ノニルフェノール（4-NP，異性体混合物，分岐型），4-n-ノニルフェノール（4-n-NP，直鎖型）及び重水素化 4-t オクチルフェノール 4-t-OP(d) は林純薬工業製の環境分析用試薬，4-t-オクチルフェノール（4-t-OP，分岐型）及び 4-n-オクチルフェノール（4-n-OP，直鎖型）は関東化学製の環境分析用試薬を用いた．

　β-グルクロニダーゼ：Sigma 製 Type H-2（β-glucuronidase 115000 units/mL, sulfatase 4500 units/mL）．

　標準溶液：各標準品 20 mg を精秤し，メタノール 100 mL に溶解して標準原液を調製し，適宜 70% メタノールで希釈して標準溶液とした．

[1] 埼玉県衛生研究所：338-0824　埼玉県さいたま市桜区上大久保 639-1
[2] 星薬科大学薬品分析化学教室：142-8501　東京都品川区荏原 2-4-41
[3] 東海大学医学部：259-1193　神奈川県伊勢原市望星台

Table 1 Operating conditions of LC/MS for octylphenol and nonylphenol

MS conditions		HPLC conditions	
Ionization	ESI, Negative	Column	Cadenza CD-C18 (100 × 2 mm)
Fragmentor	100 V	Eluent	Gradient
Nebulizer	N_2 (30 psi)	Flow rate	0.2 mL/min
Drying gas	N_2 (10 L/min, 350℃)	Oven temp.	40℃
V-cap	4500 V	Injection size	20 μL
SIM ion	m/z 205.1, 210.1, 219.1		

A = 50% acetonitrile (containing 0.005% acetic acid, 1 mM ammonium acetate); B = acetonitrile

Time/min	A, %	B, %
0	80	20
10	40	60
20	30	70

Isolute multimode カートリッジ（500 mg）: International Sorbent Technology Ltd. 製，カートリッジはあらかじめメタノール 10 mL 及び水 5 mL の順で洗浄した後使用した．

その他の試薬はすべて特級品あるいは HPLC 用を用いた．精製水の調製にはオルガノ製超純粋製造装置 Model-S を使用した．

2·2 装置及び測定条件

高速液体クロマトグラフ/質量分析計: Agilent 製 1100 series LC/MSD を使用した．測定条件は Table 1 に示した．

2·3 検量線の作成

安定同位体標識内部標準物質 4-t-OP(d_5) を 10 ng 含んだ 4-NP，4-n-NP，4-t-OP 及び 4-n-OP の 1.0，2.0，5.0，10 及び 50 ng/mL の混合標準溶液を調製し，その 20 μL を高速液体クロマトグラフ/質量分析計に注入する．検出には選択イオン検出（selected ion monitoring, SIM）法を採用し，それぞれモニターイオンにより得られた SIM クロマトグラムよりピーク面積を求め，4-NP，4-n-NP，4-t-OP 及び 4-n-OP と 4-t-OP(d_5) の面積比より検量線を作成した．

2·4 試験溶液の調製

試料 5 g を取り，メタノール 15 mL 及び内部標準 4-t-OP(d_5) 50 ng を加えてホモジナイズ抽出後，遠心分離し，上澄みを分取した．必要に応じてメタノールを加え，上澄みの全量を 15 mL とした．上澄み 3 mL（試料 1 g 相当）を取り，精製水 7 mL を加えた後，Isolute multimode カートリッジに負荷し，カートリッジを 50% メタノール 3 mL で洗浄後，メタノール 5 mL で溶出した．溶出液に 0.1 M KOH 溶液 0.1 mL を加え，窒素気流下で約 0.1 mL に減圧濃縮後，70% メタノールで 1.0 mL とした．抱合体

の分析は，上澄み 3 mL に 0.2 M 酢酸緩衝液（pH 5.0）2 mL，精製水 5 mL 及び β-グルクロニダーゼ 30 μL を加え，十分混合した後，37℃ で 10 時間インキュベートした．その後の操作は上記に示した遊離体と同様に行った．

2·5 包装材の溶出試験

市販魚介類の包装材に使用されていたラップフィルム及びトレイからの NP 及び OP の溶出試験は次のように行った．ラップフィルム，トレイを 5×5 cm に切り取ったものを内径 9 cm のガラス製シャーレに入れ，n-ヘプタン 25 mL ｛4-t-OP(d_5)，20 ng 含む｝を加えて時々振とうしながら室温で 60 分間浸漬した．n-ヘプタン溶液に KOH 溶液 0.1 mL を加え，窒素気流下で約 0.1 mL に減圧濃縮後，70% メタノールで 2.0 mL とし，試験溶液とした．

3 結果及び考察

3·1 LC/MS 測定条件の検討

一般に，工業用としては NP 及び OP 共に分岐タイプの 4-NP 及び 4-t-OP が用いられている．したがって，環境中から検出される NP, OP は分岐タイプのものである[12][13]．そこで，分岐タイプの 4-NP 及び 4-t-OP を中心に，試薬標準品として市販されている直鎖タイプの 4-n-NP 及び 4-n-OP も含めて LC/MS 測定条件を検討した．

NP は疎水性が高いことから，インターフェースには大気圧化学イオン化（atmospheric pressure chemical ionization, APCI）法が利用されている．一方，最近では操作性に優れているエレクトロスプレーイオン化（electrospray ionization, ESI）法を用いた NP, OP の分析法も数多く報告されている．そこで，APCI 法及び ESI 法を用いて検出感度を比較した結果，いずれの成分も感度的に同程度であった．そこで，インターフェースには操作性に優れている ESI 法を選択した．次に，イオン化モードを検討した結果，いずれもフェノール性水酸基を有していることから negative mode が適していた．また，移動相に微量の酢

Fig. 1　Typical LC/ESI/MS-SIM chromatograms of standard mixture (1 ng/mL)

酸及び酢酸アンモニウムを加えることにより，各成分共より高感度に検出された[14]．しかし，酢酸及び酢酸アンモニウムの濃度が高くなるに従い検出感度は逆に低下することから，酢酸濃度は 0.005%，酢酸アンモニウム濃度は 1 mM とした．更に，分析対象物質間の疎水性が大きく異なることから，グラジエント溶出法を採用した．なお，検出感度に及ぼすカラムの影響も見られ，検討した中では Cadenza CD-C18（インタクト製）が最も優れていた．

次にイオン強度に及ぼすフラグメンター電圧の影響を検討した結果，各成分の脱プロトン化分子 [M－H]$^-$（m/z 205.1，219.1，210.1）を効率良く生成する 100 V に設定した．更に，他のパラメーターの最適測定条件を検討し，Table 1 に示す条件を設定した．本条件によって得られた 4-NP，4-n-NP，4-t-OP，4-n-OP の検出限界は，SIM モードで 0.5 ng/mL（絶対量として 10 pg）であった．本法による検量線はいずれも 0.5～50 ng/mL の範囲で良好な直線性を示した．混合標準溶液 1 ng/mL の代表的な LC/ESI/MS-SIM クロマトグラムを Fig. 1 に示す．

3・2　前処理法の検討

3・2・1　抽出及びクリーンアップ　試料の前処理法の開発に当たっては実験器材や試薬からの汚染を極力少なくすることが求められる[15]．実際，前処理法を構築するに当たり，実験環境や実験器材・試薬から 4-NP の微量汚染が問題となった．そこで，より信頼性の高い前処理法を構築するため，4-NP の溶出量が少なくかつクリーンアップ効果に優れたカートリッジを検討した．その結果，Isolute multimode が最も夾雑成分の除去効果に優れ，かつ 4-NP の溶出量が少なかった（0.2 ng/cartrigde 以下）．なお，ガ

ラスバイアル瓶のキャップに用いるセプタムからも NP の汚染がみられるものもあった．セプタムには NP の溶出のない両面テフロン用を選択した．本法により得られた代表的なシジミ及びツブ貝抽出液のクロマトグラムを Fig. 2，3 に示す．なお，試料によっては 4-n-NP の溶出位置に妨害ピークが出現し，分析が困難な場合があった．工業用としては専ら分岐タイプの 4-NP が使用されていることから，これ以降直鎖タイプの 4-n-NP は分析対象から除外することにした．

3・2・2　酵素による加水分解　魚介類や哺乳類に摂取された NP，OP は，グルクロン酸抱合体又は硫酸抱合体として存在する可能性が高いことから[16]～[19]，抱合体も分析対象とした．4-t-OP 及び 4-NP 抱合体（約 500 ng/mL）を含む溶液 100 μL を 2・4 に記載した試料上澄み 3 mL に添加して加水分解条件を検討した．β-グルクロニダーゼ量を 10，30 及び 50 μL と変えて加水分解率に及ぼす影響を調べた結果，いずれの量においても 37℃，5 時間インキュベートすることによりほぼ完全に加水分解された．そこで，本法では酵素量は 30 μL，インキュベーション時間は 10 時間とした．

3・2・3　酵素反応に及ぼす MeOH 含量の影響　次に，試料抽出液がメタノールであることから，酵素反応に及ぼす MeOH 含量の影響を検討した．酵素反応溶液中のメタノール含量を 0，10，20，30，40，50，60% と変えて β-グルクロニダーゼの酵素活性に及ぼす影響を調べた．その結果，メタノール含量が 50% までは酵素活性はほとんど阻害されず，抱合体の 90% 以上が加水分解された．そこで，上澄みであるメタノール抽出液 3 mL に 0.2 M 酢酸緩衝液 2 mL 及び精製水 5 mL を加え，インキュベートする

Fig. 2 Typical LC/ESI/MS-SIM chromatograms of (A) before and (B) after deglucuronidation of freshwater clam extracs


Fig. 3 Typical LC/ESI/MS-SIM chromatograms of (A) before and (B) after deglucuronidation of grain shellfish extract

ことにした.

3・2・4 0.1 M KOH による揮散防止効果　NP，OP は減圧乾固時に揮散し，特に分岐タイプの多くが損失した|メタノールで調製した 10 ng/mL 混合標準溶液 1 mL を 40℃，10 分間減圧乾固したときの残存量は，4-NP = 16%，

4-n-NP = 82%，4-t-OP = 9%，4-n-OP = 52%，4-t-OP(d5) = 10% であった）．そこで，NP，OP が弱酸性を有するフェノール化合物であることから，0.1 M KOH 溶液 0.1 mL を乾固時に加えることにより揮散を抑制可能か検討した．0.1 M KOH 溶液 0.1 mL を加えることにより，

Table 2　Recoveries of octylphenol and nonylphenol from fish, shellfish and meat

Sample	Recovery (mean ± S.D., n = 5), %			
	4-t-OP	4-n-OP	4-NP	4-t-OP(d$_5$)
Yellowtail	85.6 ± 7.6	73.3 ± 6.2	84.2 ± 9.1	86.3 ± 5.7
Freshwater clam	89.6 ± 5.7	81.3 ± 5.6	86.3 ± 7.8	84.7 ± 4.8
Pork	81.3 ± 7.2	72.1 ± 6.6	79.5 ± 8.3	83.3 ± 6.7

Samples were spiked with 10 ng/g of each drug.

Table 3　Concentration of OP and NP in fish, shellfish and meat

Sample	Inspection number	Free (non-deglucuronidation)			Total (deglucuronidation)		
		4-t-OP	4-n-OP	4-NP	4-t-OP	4-n-OP	4-NP
Horse mackerel	3	ND	ND	ND	ND	ND	ND
Yellowtail	2	ND	ND	ND	ND	ND	ND
Sardine	2	ND	ND	ND	ND	ND	ND
Rainbow trout	2	ND	ND	ND	ND	ND	ND
Flounder	1	ND	ND	ND	ND	ND	ND
Sweet fish	2	ND	ND	ND	ND	ND	ND
Mackerel	1	ND	ND	ND	ND	ND	ND
Pacific saury	1	ND	ND	ND	ND	ND	ND
Shad	1	ND	ND	ND	ND	ND	ND
Striped pigfish	1	ND	ND	ND	ND	ND	ND
Freshwater clam	7	Tr	ND	ND ~ 64.1	1.0	ND	ND ~ 88.9
Littleneck clam	3	ND	ND	ND ~ 2.0	ND	ND	ND ~ 2.7
Clam	3	ND	ND	ND	ND	ND	ND
Grain shellfish	2	ND	ND	4.3 ~ 15.7	ND	ND	5.4 ~ 13.3
Scallop	2	ND	ND	ND	ND	ND	ND
Turban shell	1	ND	ND	ND	ND	ND	ND
Sea snail	1	ND	ND	ND	ND	ND	ND
Surf clam	1	ND	ND	ND	ND	ND	ND
Sea squirt	1	ND	ND	ND	ND	ND	ND
Wakame seaweed	6	ND	ND	ND ~ 14.3	ND	ND	ND ~ 11.0
Chicken	3	ND	ND	ND	ND	ND	ND
Pork	3	ND	ND	ND	ND	ND	ND
Beef	3	ND	ND	ND	ND	ND	ND

ND：4-t-OP < 0.5 ppb, 4-n-OP < 0.5 ppb, 4-NP < 2.0 ppb

いずれの成分も 95% 以上残存した．なお，減圧濃縮時の
ロータリエバポレーターからの 4-NP の汚染を防ぐため
に，エバポレーター内はよく洗浄し，減圧濃縮は窒素気流
下で行った．

3・3　添加回収実験

4-NP，4-t-OP，4-n-OP 及び内部標準 4-t-OP(d$_5$) を，ハ
マチ，シジミ及び豚肉に 10 ng/g の濃度で添加し，回収
率を求めた．その結果，ハマチ，シジミ及び豚肉はいずれ
の成分も 70% 以上の回収率であった〔Table 2，4-t-
OP(d$_5$) での補正なし〕．本法による 4-t-OP，4-n-OP の検
出限界は 0.5 ng/g（S/N 3）であった．一方，4-NP はハ
マチ及びシジミ共に操作空試験値（最終試験溶液 1 mL に
対して 0.32 ± 0.18 ng/mL）が観測された．一般に操作空
試験値が観測された場合の検出限界 LOD は，操作空試験
値の平均値プラス標準偏差の 3 倍と定義されている．し
たがって，試料中の 4-NP の検出下限値は信頼性を考慮し

て 2 ng/g とした．

3・4　魚介類，食肉中の NP，OP 濃度

本法により，埼玉県内で市販されていた魚介類，食肉等，
計 52 検体を分析した．今回分析した中では，一部のシジ
ミ（7 検体中 2 検体），ツブ貝（2 検体中 2 検体）及びワ
カメ（6 検体中 1 検体）から微量の 4-NP が検出された．
また，4-NP が 88.9 ng/g 検出されたシジミからは，同時
に 1 ng/g の 4-t-OP も検出された．

ヒトやラット，マウス等では NP，OP は経口摂取後，速
やかにグルクロン酸抱合体に代謝され，血中や尿中には主
にグルクロン酸抱合体として存在するとされている[16)~19)]．
一方，貝類からの NP 検出例に関する報告はなされている
が，遊離体のみ測定しており，代謝に関する報告は見られ
ない[20)21)]．そこで，今回の調査で微量の 4-NP が検出され
たシジミ及びツブ貝について，遊離体と抱合体を含めた総
量を測定した．Table 3 に示すとおり，シジミ及びツブ貝

Table 4　Thermal stability of residual 4-nonylphenol in freshwater clam and grain shellfish

Sample		NP	Rate, %
Freshwater clam	Boil liquid	3.4 ng/100 mL	1.0
	tissues	337.1 ng (61.4 ng g^{-1})	99.0
Grain shellfish	Boil liquid	2.5 ng/100mL	2.2
	tissues	108.7 ng (15.1 ng g^{-1})	97.8

Ten pieces of freshwater clam and one piece of grain shellfish were boiled in 100 mL of water for 5 minutes, respecrively.

中から検出された 4-NP は，その多くが遊離体であり，抱合体はほとんど検出されなかった．このことから，シジミ，ツブ貝のグルクロン酸抱合化活性は低いと考えられる．

　次に，シジミ及びツブ貝中含まれる 4-NP の加熱調理における安定性を調べた．シジミ 10 粒，ツブ貝 1 粒をそれぞれ 100 mL の沸騰水中で 5 分間加熱調理後，沸騰水中への移行量及びシジミ，ツブ貝中の濃度を調べた．貝中に含まれる 4-NP は沸騰水中にはほとんど移行せず，貝中に残存していた（Table 4）．また，加熱処理後においてもその濃度に変化はほとんど見られず，安定であった．なお，Fig. 2，3 に市販魚介類の代表例として 4-NP が検出されたシジミ及びツブ貝抽出液の LC/ESI/MS-SIM クロマトグラムを示した．

3・5　魚介類中の NP 濃度と包装材の影響

　魚介類の NP 及び OP 汚染の原因として，環境汚染由来によるものと，魚介類が包装されていた包装材由来によるものが報告されている[9,10]．そこで，今回の調査で NP が検出されたシジミ（2 検体）及びツブ貝（2 検体）について，これらの検体が包装されていた包装材（ラップフィルム，トレイ）について，NP 及び OP の溶出試験を行った．その結果，今回 NP が検出されたシジミ及びツブ貝に用いられていた包装材からの NP 及び OP の溶出量は，いずれも 1 ng/cm^2 以下であった．更に，シジミ及びツブ貝は，殻は包装材と接触しているが，貝の中身は接触していない．以上のことから，今回 NP が微量検出された貝類の汚染原因は，包装材からの影響は極めて少なく，環境汚染由来によるものと考えられる．

4　結　語

　最近，NP，OP は魚類に対して内分泌撹乱作用を示すことが明らかにされた．しかし，魚類と異なりラットやマウス等の哺乳類に対するエストロゲン様作用は非常に弱いとされている．更にその代謝体であるグルクロン酸抱合体は，エストロゲン様作用をほとんど示さないとされている．今回，市販魚介類，食肉等計 52 検体を分析した結果，一部のシジミ等を除き，4-NP，4-t-OP は検出限界以下であった．分析数が少なく，今回の調査から我々が食してい

る多くの食品中の NP，OP レベルを評価することは困難である．しかし，NP，OP の界面活性剤への使用が年々大きく減少しており，NP，OP の河川水や水道源水中の汚染レベルは年々低下している．また，食品への移行が考えられる容器包装への使用も少なくなっている．したがって，我々が暴露されている OP，NP の量は極めて少ないレベルであると推定される．今後，我々が食品等を経由して摂取する OP，NP 量は更に減少していくと考えられる．

文　献

1) A. M. Soto, H. Justicia, J. W. Wray, C. Sonnenschein : *Environ. Health Perspect.*, **92**, 167 (1991).
2) R. White, S. Jobling, S. A. Hoare, J. P. Sumpter : *Endocrinology*, **135**, 175 (1994).
3) W. Ginger, P. H. Brunner, C. Schaffner : *Science*, **225**, 623 (1984).
4) M. Ahel, W. Giger, M. Koch : *Water. Res.*, **28**, 1131 (1994).
5) J. P. Sumpter, S. Jobling : *Environ. Health Perspect.*, **103**, 173 (1995).
6) D. Y. Shang, R. W. Macdonald, M. G. Ikonomou : *Environ. Sci. Technol.*, **33**, 1366 (1999).
7) 環境省総合環境政策局環境保健部編：「ノニルフェノールが魚類に与える内分泌撹乱作用の試験結果に関する報告」(2001 年 8 月).
8) 環境省総合環境政策局環境保健部編：「魚類を用いた生態系への内分泌撹乱作用に関する試験結果について」(2002 年 6 月).
9) 佐々木久美子, 高附　功, 根本　了, 今中雅章, 衛藤修一, 村上恵美子, 豊田正武：食品衛生学雑誌, **40**, 460 (1999).
10) 根本　了, 高附　功, 佐々木久美子, 豊田正武：食品衛生学雑誌, **41**, 377 (2000).
11) 樋口雅之, 宮田大典, 川村誠二, 植田英一, 今中雅章, 外海泰英：食品衛生学雑誌, **45**, 339 (2004).
12) T. Nishihara, J. Nishikawa, T. Kanayama, F. Dakeyama, K. Saito, M. Imagawa, S. Takatori, Y. Kitagawa, S. Hori : *J. Health Sci.*, **46**, 282 (2000).
13) M. Petrovic, A. Diaz, F. Ventura, D. Barcelo : *Anal. Chem.*, **73**, 5886 (2001).
14) 堀江正一, 吉田栄充, 石井里枝, 小林　進, 中澤裕之：分析化学 (*Bunseki Kagaku*), **48**, 579 (1999).
15) 厚生労働省医薬局化学物質安全対策室編：「内分泌かく乱化学物質の健康影響に関する検討会　中間報告書追補」(平成 13 年 12 月).
16) S. Muller, P. Schmid, C. Schlatter : *Environ. Toxicol. Pharmacol.*, **5**, 257 (1998).
17) D. R. Doerge, N. C. Twaddle, M. I. Churchwell, H. C.

Chang, R. R. Newbold, K. B. Delclos: *Reproductive Toxicol.*, **16**, 45 (2002).
18) A. Arukwe, A. Goksoyr, R. Thibaut, J. P. Cravedi: *Marine Environ. Research*, **50**, 141 (2000).
19) K. Inoue, M. Kawaguchi, F. Okada, N. Takai, Y. Yoshimura, M. Horie, S. Izumi, T. Makino, H.

Nakazawa: *Anal. Chim. Acta*, **486**, 41 (2003).
20) T. Tuda, K. Suga, E. Kaneda, M. Ohsuga: *J. Chromatogr. B*, **746**, 305 (2000).
21) T. Tuda, K. Suga, E. Kaneda, M. Ohsuga: *Bull. Environ. Contam. Toxicol.*, **68**, 126 (2002).

Determination of Nonylphenol and Octylphenol in Fish and Shellfish by High-Performance Liquid Chromatography/Electrospray Mass Spectrometry

Masakazu Horie[1], Harumi Kobayashi[1], Rie Ishii[1], Koichi Saito[2],

Hiroyuki Nakazawa[2] and Tsunehisa Makino[3]

[1] Saitama Prefectural Institute of Public Health, 639-1, Kamiokubo, Sakura-ku, Saitama-shi, Saitama 338-0824
[2] Department of Analytical Chemistry, Hoshi University, 2-4-41, Ebara, Shinagawa-ku, Tokyo 142-8501
[3] School of Medicine, Tokai University, Bohseidai, Isehara-shi, Kanagawa 259-1193

A simple and reliable method using liquid chromatography-electrospray ionization-mass spectrometry (LC/ESI-MS) has been developed for the determination of 4-nonylphenol (4-NP) and 4-octylphenol (4-OP) in seafood and meat. LC separation was performed on a Cadenza CD-C18 column (100 × 2 mm i.d.) with a gradient system of 50% acetonitrile (containing 1 mM ammonium acetate and 0.005% acetic acid)-acetonitrile as the mobile phase at a flow rate of 0.2 mL/min. The negative ionization produced molecular related ions: $(M-H)^-$, at m/z 205.1 and 219.1 for 4-OP and 4-NP, respectively. The calibration graphs for 4-NP and 4-OP were rectilinear from 0.5 to 50 ng/mL with selected ion monitoring (SIM). The compounds were extracted with methanol, and the extracts were cleaned up on a Isolute Multimode cartridge (500 mg). The method involves enzymatic deconjugation by β-glucuronidase and correction of the stable isotopically labeled internal standard, 4-octylphenol-d type. The recoveries of the compounds from seafood fortified at a level 10 ng/g was 72.1～89.6%, with high precision. The limits of detection of the compounds in seafood were 0.5～2 ng/g.

Keywords : nonylphenol; octylphenol; alkylphenol; seafood; fish; LC; mass spectrometry; LC/MS.

MEASUREMENT OF PERFLUORINATED COMPOUNDS IN HUMAN MILK AND HOUSE DUST

Nakata A[1], Katsumata T[1], Iwasaki Y[1], Ito R[1] Saito K[1] Izumi S[2], Makino T[2], Kishi R[3], Nakazawa H[1]

[1] Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Hoshi University, 2-4-41, Ebara Shinagawa-ku, Tokyo, 142-8501, Japan; [2] Department of Obstetrics and Gynecology, Tokai University School of Medicine, 143, Shimokasuya, Isehara-shi, 259-1193, Japan; [3] Department of Public Health, Hokkaido University Graduate School of Medicine, Department of Public Health, North 15 West 7 Kita-ku, Sapporo, 060-8501, Japan;

Abstract

The purpose of the present study is to evaluate the exposure sources of perfluorinated compounds (PFCs) for infants. Highly sensitive methods for measuring four kinds of PFCs (perfluorooctanesulfonate; PFOS, perfluorooctanoic acid; PFOA, perfluorononanoic acid; PFNA and perfluorohexanesulfonate; PFHxS) in house dust and human milk were developed using liquid chromatography tandem mass spectrometry (LC/MS/MS). The average recovery which was assessed at two different concentrations were more than 97.9% in house dust samples and 94.3 % in human milk samples, respectively. The detection limits of the methods for each PFCs were assessed as being 0.58 ng/g to 0.72 ng/g in house dust and 0.004 ng/mL to 0.1 ng/mL in human milk. To investigate the source of PFCs exposure for infants, house dust samples (n = 20) and breast milk samples (n = 51) were measured by the developed methods. PFOS and PFOA were detected in all dust samples (PFOS: 7.0 to 41 ng/g; PFOA: 18 to 89 ng/g). In human milk sample, PFOS was detected in all samples with the range from 0.008 to 0.401 ng/mL. Based on our experiments, house dust or human milk might be one of the human exposure sources of PFCs.

Introduction

Perfluoronated compounds (PFCs), such as perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA), which have their biological and chemical stability are widely used in the manufacture of plastic, electronics, textile, and construction material in the apparel, leather, and upholstery industries[1]. However, PFCs may be detrimental to rodent development possibly affecting thyroid hormone levels, so affect of PFCs on infant is concerned[2]. Moreover, environmental pollution and human exposure[3,4,5] of PFCs have been reported. According to these studies, PFCs level in human blood is significantly higher than that in environment. So, it is very important to elucidate human exposure of PFCs. House dust is a curious sample to give an assessment of PFCs exposure in infant who is exposed though maternal feeding as indoor environment. PFCs level of human milk is very low compared to that of human blood, but infant takes a lot of milk during lactational period, so it is required to estimate intake amount of PFCs. Although human exposure of PFCs is widely reported, very few information about exposure source of PFCs have indicated so far. In this study, we have developed an analytical method for the determination of PFCs in house dust and human milk by liquid chromatography tandem mass spectrometry (LC/MS/MS) to investigate exposure source of PFCs.

Materials and Methods

Chemicals: Perfluorohexane sulfonate (PFHxS; 98%) was purchased from Wellington Laboratories Inc., Japan. Perfluorooctane sulfonate (PFOS; 98%) were purchased from Wako Pure Chemicals Industries, Ltd., Japan. perfluorooctanoic acid (PFOA; >90%) and perfluorononanoic acid (PFNA; 95%) were purchased from Fuluka Chemie AG, Buchs, Switzerland. $^{13}C_4$-PFOS was purchased from Wellington Laboratories Inc., Japan. $^{13}C_2$-PFOA was purchased from PerkinElmer Inc., USA. Other chemicals were purchased from Wako Pure Chemicals Industries, Ltd., Japan Water was purified using a Milli-Q cartridge system (Millpore, Bedford, MA, USA).

Instrumentation and analytical conditions of LC/MS/MS:

LC/MS/MS analysis was performed using a Waters Quattro micro system. Separation was achieved on an Xbridge column (2.1 × 50 mm, 2.1 μm, Waters Inc., Japan). The column oven was maintained at 40°C. The separation was carried out using a mobile phase of 1.0 mM ammonium acetate in water/acetonitrile at a flow rate of 0.2 mL/min. The gradient profile of mobile phase was as follows: 0-10 min. using a linear increase from 10 to

70% acetonitrile solution, and holding at 70%. The conditions of MS/MS were as follows: the desolvation and source temperatures were set at 350 and 100°C, respectively; the capillary was held at a potential of 600 V relative to the counter electrode in the negative ion mode for all compounds. The cone gas and desolvation gas were 50 and 350 L/hr, respectively. The cone and collision voltage were 48 and 40 V for PFHxS, 60 and 65 V for PFOS, and 14 and 11 V for PFOA, 18 and 10 V for PFNA, respectively.

Sample preparation of human milk sample by solid phase extraction

Because of very low concentrations of PFCs in the sample matrix, the solid phase extraction (SPE) has been applied for the sample extraction and concentration. The average extraction recoveries for PFCs and relative standard deviation (R.S.D.) were over 94.3% and 10.3%, respectively. The milk samples were extracted using a solid-phase extraction cartridge (Waters Oasis WAX, Milford, MA, USA). Internal standards ($^{13}C_2$-PFOA and $^{13}C_4$-PFOS) and 15 mL of 0.1 mol/L formic acid were added to 5 mL of milk. The solution was sonicated for 15 min and centrifuged at 6000 rpm for 15 min. The supernatant was loaded onto the cartridge and rinsed by wash solvent. The PFCs were eluted from the SPE cartridge with 3 mL of 3% ammonium hydroxide in acetone. The extracts were concentrated by dry nitrogen stream, and finally, filtered through a nylon membrane filter. The final sample volume for the milk extracts was adjusted to 100 μL. This SPE method using the Oasis WAX® was successfully used for the pretreatment of PFCs in human milk samples.

Sample preparation of house dust sample by SFE

House dust sample were contained several compounds. It was necessary to clean up for the determination of PFCs. We tried to use Supercritical fluid extraction (SFE) method for PFCs extraction in house dust. First of all, the dust samples were collected from the dust bags of vacuum cleaners from residential homes in Japan, and were passed though two different size of sieves (mesh size: 1 mm and 75 μm). The relatively large solids and minute powders were removed. The selected dust samples having a particle size of 75 μm-1 mm were used for analysis. A 0.5 g of house dust was charged in cell for SFE and internal standard was added. Then, the samples were extracted for one hour by SFE at 0.5 mL/min with carbon dioxide as extraction solvent, and 4% v/v methanol were added as a modifier. The SFE extract was got through same procedure on human milk samples. The final volume for the dust extracts was adjusted to 2.5 mL.

Result and Discussion

Validation of the LC/MS/MS method:

To validate of the LC/MS/MS method, several experimental parameters, such as limit of detection (LOD) and limit of quantitation (LOQ), were examined. LOD was 0.08 to 0.15 ng/mL in house dust sample. LOQ was 0.004 to 0.1 ng/mL and 0.5 ng/mL in human milk and house dust, respectively (S/N = 10). The calibration curves were obtained by analyzing mixtures containing and the internal standard in the range from 0.2 to 20 ng/mL for PFCs, respectively. The average recoveries and relative standard deviation (R.S.D.) were over 94.3 and 10.3% for PFCs at the spiked. On the other hand, the average recoveries and relative standard deviation (R.S.D.) were over 93.4% and 8.6% for PFCs at the spiked. Our methods were enabled to prepare in the human milk and the house dust samples.

Determination of PFCs in human milk and house dust samples:

The proposed method was applied to the analysis of human milk samples from healthy mother volunteers. The representative chromatogram of the milk sample is shown in Fig. 1. PFCs were detected in all the samples, and PFOS from the milk samples ranged from 0.008 to 0.4 ng/mL, as shown in Table 1. The house dust samples were relatively high concentrations of PFCs were detected (Table 2).

Fig. 1 Chromatogram of PFCs in the milk sample

Table 1 Concentration of PFCs in human milk samples

Compound	Detection rate (%)	Maximum (ng/mL)	Minimum (ng/mL)
PFHxS	64	0.025	N.D.
PFOS	100	0.401	0.008
PFOA	44	0.339	N.D.
PFNA	86	0.150	N.D.

Table 2 Concentration of PFCs in house dust samples

Compound	Detection rate (%)	Maximum (ng/g)	Minimum (ng/g)
PFHxS	40	5.5	N.D.
PFOS	100	41.0	7.0
PFOA	100	88.5	17.5
PFNA	100	69.0	5.5

Conclusion

The proposed LC/MS/MS method enabled the simultaneous determination of PFCs in human milk and house dust samples. In addition, interferences from sample matrice were removed by using the SPE for human milk or SFE for house dust, respectively. To investigate the source of PFCs exposure for infants, house dust samples (n = 20) and human milk samples (n = 51) were measured by developed methods. PFOS and PFOA were detected in all dust samples (PFOS: 7.0 to 41 ng/g; PFOA: 18 to 89 ng/g). Based on our results, house dust might be one of exposure sources of PFCs. Further studies are necessary to make sure the exposure source of PFCs for infant from indoor condition. In addition, PFOS was also detected in all samples in human milk (PFOS: 0.008 to 0.401 ng/g;). The infants will be exposed to PFCs from not only the umbilical cord blood but also human milk with maternal feeding.

References

1. M. E. Austin, B. S. Kasturi, M. Barber, K. Kannan, P. MohanKumar, S. M. J. MohanKumar, *Environ. Health. Perspect.*, 2003;35:111:
2. J. R. Thiboeaux, R. G. Hanson, J. M. Rogers, B. E. Grey, B. D. Barbee, J. H. Richards, J. L. Butenhoff, L. A. Stevenson, C.Lau., *Toxiclol. Sci.*, 2003;74:369
3. K.Inoue, F.Okada, R.ITO, S.Kato, S.Sasaki, S.Nakajima, A.Uno, Y.Saijo, F.Sata, Y.Yoshimura, R.Kishi, H.Nakazawa : *Environ. Health Perspect.*, 2004;112:1204
4. A. Karrman, B. B. Van, U. Jarnberg, L. Hardell, G. Lindstrom, *Anal. Chem.*, 2005;77:864
5. M. K. SO, S. Taniyasu, N, Yamashita, J. P. Giesy, J. Zheng, Z. Fang, S. H. IM, P. K.S. Lam., *Environ. Health. Technol.*, 2005;38:4056